China, India making inroads in biotech drugs
Chinese and Indian drug makers have taken over much of the global trade in medicines and now manufacture more than 80% of the active ingredients in drugs sold worldwide. Gardiner Harris reports.Updated: Sep 20, 2011 01:48 IST
Chinese and Indian drug makers have taken over much of the global trade in medicines and now manufacture more than 80% of the active ingredients in drugs sold worldwide.
But they had never been able to copy the complex and expensive biotech medicines increasingly used to treat cancer, diabetes and other diseases in rich nations like the United States — until now.
These generic drug companies say they are on the verge of selling cheaper copies of such huge sellers as Herceptin for breast cancer, Avastin for colon cancer, Rituxan for non-Hodgkin’s lymphoma and Enbrel for rheumatoid arthritis.Their entry into the market in the next year — made possible by hundreds of millions of dollars invested in biotechnology plants — could not only transform the care of patients in much of the world but also ignite a counterattack by major pharmaceutical companies and diplomats from richer countries.
Already, the Obama administration has been trying to stop an effort by poorer nations to strike a new international bargain that would allow them to get around patent rights and import cheaper Indian and Chinese knock-off drugs for cancer and other diseases, as they did to fight Aids.
Although the draft agreement for this week’s world leader’s meeting at the United Nations offers no support for poor nations seeking freer patent rules to fight cancer and other noncommunicable diseases, their advocates have vowed to continue fighting to loosen those restrictions not only this week in New York but in continuing international trade negotiations around the world as well.
(The New York Times)
First Published: Sep 19, 2011 23:51 IST